Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells

Proteomics

Volumn 11, Issue 12, 2011, Pages 2528-2541

  Seliger, Barbara ^a   Dressler, Sven P ^a   Massa, Chiara ^a   Recktenwald, Christian V ^a   Altenberend, Florian ^b   Bukur, Juergen ^a   Marincola, Francesco M ^c   Wang, Ena ^c   Stevanovic, Stefan ^b   Lichtenfels, Rudolf ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Biomarkers; Cell biology; HLA antigens; Peptide ligands; Renal cell carcinoma; T cell response

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; HLA A2 ANTIGEN; LEUKOCYTE ANTIGEN; LIGAND;

ARTICLE; CANCER INFILTRATION; CANCER PATIENT; CARCINOMA CELL; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; REGULATORY MECHANISM; T LYMPHOCYTE; TISSUE SECTION; TRANSCRIPTION REGULATION;

ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CHROMATOGRAPHY, LIQUID; CLONING, MOLECULAR; DNA, COMPLEMENTARY; EPITOPES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LIGANDS; MASS SPECTROMETRY; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDOREDUCTASES ACTING ON SULFUR GROUP DONORS; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 79958150014     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000486     Document Type: Article

References (72)

1. Scholz, C., Tampe, R., The peptide-loading complex - antigen translocation and MHC class I loading. Biol. Chem. 2009, 390, 783-794.
2. Storkus, W. J., Herrem, C., Kawabe, M., Cohen, P. A. et al., Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived peptide epitopes. Crit. Rev. Immunol. 2007, 27, 485-493.
3. Gordan, J. D., Vonderheide, R. H., Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002, 4, 317-327.
4. Jager, D., Jager, E., Knuth, A., Vaccination for malignant melanoma: recent developments. Oncology 2001, 60, 1-7.
5. Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J., Chen, Y. T., Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 2002, 188, 22-32.
6. Jager, D., Taverna, C., Zippelius, A., Knuth, A., Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol. Immunother. 2004, 53, 144-147.
7. Kawakami, Y., Robbins, P. F., Rosenberg, S. A., Human melanoma antigens recognized by T lymphocytes. Keio J. Med. 1996, 45, 100-108.
8. Maecker, B., von, B.-B., Anderson, K. S., Vonderheide, R. H., Schultze, J. L., Linking genomics to immunotherapy by reverse immunology - "immunomics" in the new millennium. Curr. Mol. Med. 2001, 1, 609-619.
9. Kruger, T., Schoor, O., Lemmel, C., Kraemer, B. et al., Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol. Immunother. 2005, 54, 826-836.
10. Otsuka, M., Kato, M., Yoshikawa, T., Chen, H. et al., Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem. Biophys. Res. Commun. 2001, 289, 876-881.
11. Seliger, B., Dressler, S. P., Lichtenfels, R., Kellner, R., Candidate biomarkers in renal cell carcinoma. Proteomics 2007, 7, 4601-4612.
12. Seliger, B., Dressler, S. P., Wang, E., Kellner, R. et al., Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics 2009, 9, 1567-1581.
13. Weinschenk, T., Gouttefangeas, C., Schirle, M., Obermayr, F. et al., Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002, 62, 5818-5827.
14. Rauch, J., Gires, O., SEREX, Proteomex, AMIDA, and beyond: serological screening technologies for target identification. Proteomics Clin. Appl. 2008, 2, 355-371.
15. Schmidt, A., Kellermann, J., Lottspeich, F., A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 2005, 5, 4-15.
16. Wu, W. W., Wang, G., Baek, S. J., Shen, R. F., Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J. Proteome Res. 2006, 5, 651-658.
17. Rajcevic, U., Petersen, K., Knol, J. C., Loos, M. et al., iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol. Cell. Proteomics 2009, 8, 2595-2612.
18. Flad, T., Spengler, B., Kalbacher, H., Brossart, P. et al., Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res. 1998, 58, 5803-5811.
19. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K. et al., Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992, 255, 1261-1263.
20. Purcell, A. W., Gorman, J. J., Immunoproteomics: mass spectrometry-based methods to study the targets of the immune response. Mol. Cell. Proteomics 2004, 3, 193-208.
21. Boss, C. N., Grunebach, F., Brauer, K., Hantschel, M. et al., Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin. Cancer Res. 2007, 13, 3347-3355.
22. Stickel, J. S., Weinzierl, A. O., Hillen, N., Drews, O. et al., HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol. Immunother. 2009, 58, 1407-1417.
23. *25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol. Ther. 2005, 4, 943-948.
24. Hofmann, S., Gluckmann, M., Kausche, S., Schmidt, A. et al., Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by nano-LC MALDI MS/MS. Mol. Cell Proteomics 2005, 4, 1888-1897.
25. Weinzierl, A. O., Lemmel, C., Schoor, O., Muller, M. et al., Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol. Cell. Proteomics 2007, 6, 102-113.
26. Woods, A. S., Huang, A. Y., Cotter, R. J., Pasternack, G. R. et al., Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. Anal. Biochem. 1995, 226, 15-25.
27. Zhen, Y., Xu, N., Richardson, B., Becklin, R. et al., Development of an LC-MALDI method for the analysis of protein complexes. J. Am. Soc. Mass Spectrom. 2004, 15, 803-822.
28. Hillen, N., Mester, G., Lemmel, C., Weinzierl, A. O. et al., Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype. Eur. J. Immunol. 2008, 38, 2993-3003.
29. Klug, F., Miller, M., Schmidt, H. H., Stevanovic, S., Characterization of MHC ligands for peptide based tumor vaccination. Curr. Pharm. Des. 2009, 15, 3221-3236.
30. Meyer, V. S., Drews, O., Gunder, M., Hennenlotter, J. et al., Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J. Proteome Res. 2009, 8, 3666-3674.
31. Dengjel, J., Nastke, M. D., Gouttefangeas, C., Gitsioudis, G. et al., Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin. Cancer Res. 2006, 12, 4163-4170.
32. Craven, R. A., Banks, R. E., Understanding and managing renal cell carcinoma: can proteomic studies contribute to clinical practice? Contrib. Nephrol. 2008, 160, 88-106.
33. Kim, D. S., Choi, Y. P., Kang, S., Gao, M. Q. et al., Panel of candidate biomarkers for renal cell carcinoma. J. Proteome Res. 2010, 9, 3710-3719.
34. Johann, D. J., Jr., Wei, B. R., Prieto, D. A., Chan, K. C. et al., Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. Anal. Chem. 2010, 82, 1584-1588.
35. Okamura, N., Masuda, T., Gotoh, A., Shirakawa, T. et al., Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics 2008, 8, 3194-3203.
36. Perroud, B., Ishimaru, T., Borowsky, A. D., Weiss, R. H., Grade-dependent proteomics characterization of kidney cancer. Mol. Cell. Proteomics 2009, 8, 971-985.
37. Lichtenfels, R., Dressler, S. P., Zobawa, M., Recktenwald, C. V. et al., Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis. Mol. Cell. Proteomics 2009, 8, 2827-2842.
38. Linehan, W. M., Bratslavsky, G., Pinto, P. A., Schmidt, L. S. et al., Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 2010, 61, 329-343.
39. O'Reilly, T., McSheehy, P. M., Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl. Oncol. 2010, 3, 65-79.
40. Rini, B. I., New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin. Cancer Res. 2010, 16, 1348-1354.
41. McGuire, B. B., Fitzpatrick, J. M., Biomarkers in renal cell carcinoma. Curr. Opin. Urol. 2009, 19, 441-446.
42. Bukur, J., Rebmann, V., Grosse-Wilde, H., Luboldt, H. et al., Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res. 2003, 63, 4107-4111.
43. Lichtenfels, R., Kellner, R., Bukur, J., Beck, J. et al., Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002, 2, 561-570.
44. Wang, E., Lichtenfels, R., Bukur, J., Ngalame, Y. et al., Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res. 2004, 64, 7279-7287.
45. Salter, R. D., Howell, D. N., Cresswell, P., Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985, 21, 235-246.
46. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., Rammensee, H. G., Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991, 351, 290-296.
47. *6601 peptide motif: prediction by pocket structure and verification by peptide analysis. Immunogenetics 1999, 49, 571-576.
48. Barnstable, C. J., Bodmer, W. F., Brown, G., Galfre, G. et al., Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978, 14, 9-20.
49. Morris, H. R., Paxton, T., Dell, A., Langhorne, J. et al., High sensitivity collisionally-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 1996, 10, 889-896.
50. Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., Stevanovic, S., SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50, 213-219.
51. Recktenwald, C. V., Kellner, R., Lichtenfels, R., Seliger, B., Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Cancer Res. 2008, 68, 10086-10093.
52. Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C. A. et al., A Human Protein Atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 2005, 4, 1920-1932.
53. Lemmel, C., Weik, S., Eberle, U., Dengjel, J. et al., Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 2004, 22, 450-454.
54. * 1516 motif demonstrates HLA-B-specific P2 pocket characteristics. Immunogenetics 1998, 48, 156-160.
55. Zhou, W., Ye, X. L., Sun, Z. J., Ji, X. D. et al., Overexpression of degenerative spermatocyte homolog 1 up-regulates the expression of cyclin D1 and enhances metastatic efficiency in esophageal carcinoma Eca109 cells. Mol. Carcinog. 2009, 48, 886-894.
56. Golovina, T. N., Morrison, S. E., Eisenlohr, L. C., The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J. Immunol. 2005, 174, 2763-2769.
57. Ostankovitch, M., Robila, V., Engelhard, V. H., Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation. J. Immunol. 2005, 174, 2544-2551.
58. Princiotta, M. F., Finzi, D., Qian, S. B., Gibbs, J. et al., Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003, 18, 343-354.
59. Shastri, N., Schwab, S., Serwold, T., Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 2002, 20, 463-493.
60. Flad, T., Mueller, L., Dihazi, H., Grigorova, V. et al., T cell epitope definition by differential mass spectrometry: identification of a novel, immunogenic HLA-B8 ligand directly from renal cancer tissue. Proteomics 2006, 6, 364-374.
61. Bakker, A. H., Hoppes, R., Linnemann, C., Toebes, M. et al., Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc. Natl. Acad. Sci. USA 2008, 105, 3825-3830.
62. Rock, K. L., Goldberg, A. L., Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 1999, 17, 739-779.
63. Saveanu, L., Fruci, D., van Endert, P., Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. Mol. Immunol. 2002, 39, 203-215.
64. Seifert, U., Maranon, C., Shmueli, A., Desoutter, J. F. et al., An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 2003, 4, 375-379.
65. Chang, S. C., Momburg, F., Bhutani, N., Goldberg, A. L., The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc. Natl. Acad. Sci. USA 2005, 102, 17107-17112.
66. Hearn, A., York, I. A., Rock, K. L., The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J. Immunol. 2009, 183, 5526-5536.
67. Serwold, T., Gonzalez, F., Kim, J., Jacob, R., Shastri, N., ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002, 419, 480-483.
68. York, I. A., Mo, A. X., Lemerise, K., Zeng, W. et al., The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 2003, 18, 429-440.
69. Towne, C. F., York, I. A., Watkin, L. B., Lazo, J. S., Rock, K. L., Analysis of the role of bleomycin hydrolase in antigen presentation and the generation of CD8 T cell responses. J. Immunol. 2007, 178, 6923-6930.
70. Stoltze, L., Schirle, M., Schwarz, G., Schroter, C. et al., Two new proteases in the MHC class I processing pathway. Nat. Immunol. 2000, 1, 413-418.
71. Chang, T. S., Jeong, W., Woo, H. A., Lee, S. M. et al., Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J. Biol. Chem. 2004, 279, 50994-51001.
72. Wei, Q., Jiang, H., Matthews, C. P., Colburn, N. H., Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. Proc. Natl. Acad. Sci. USA 2008, 105, 19738-19743.